Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-20/19-T in Relapsed/Refractory B-cell ALL
NCT04049383Phase 1Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2020
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of zamtocabtagene autoleucel in acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Number of Adverse Events after CAR 20/19-T Cell Infusion at 28 days. Started Oct 2020; status: terminated.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04049383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049383.